Non-inferiority Study of Unresectable Hepatocelluar Carcinoma Receiving Stereotactic Radiotherapy Combined With Hepatic Arterial Chemoembolization Compared With Conversion Hepatectomy
NCT05057104 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 320
Last updated 2021-09-27
Summary
To compare the prognosis and adverse reactions of unresectable hepatocellular carcinoma receiving stereotactic radiotherapy combined with hepatic arterial chemoembolization and conversion hepatectomy
Conditions
- Hepatocellular Carcinoma Non-resectable
- Conversion
Sponsors & Collaborators
-
Beijing 302 Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-10-10
- Primary Completion
- 2024-12-31
- Completion
- 2024-12-31
More Related Trials
-
Preoperative Stereotactic Body Radiotherapy (SBRT) Followed by Hepatectomy for Centrally Located Hepatocellular Carcinoma: a Prospective, Single-center, Phase I Study
NCT05598060 ·Status: UNKNOWN ·Phase: NA
-
Combination Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma Greater Than 3 cm
NCT00479050 ·Status: COMPLETED ·Phase: PHASE1
-
Combination of SFRT, PD-L1 Inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma
NCT06708650 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Comparison of Efficacy in SBRT of HCC ≤5 cm With or Without TACE
NCT04161287 ·Status: UNKNOWN
-
Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma
NCT05031949 ·Status: RECRUITING ·Phase: PHASE1
-
Study on the Efficacy and Safety of Conversion Therapy in Patients With Initially Unresectable Hepatocellular Carcinoma
NCT06365034 ·Status: RECRUITING
-
Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT
NCT06349317 ·Status: RECRUITING ·Phase: PHASE2
-
Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma
NCT02851784 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma With Major Portal Vein Invasion
NCT01850368 ·Status: COMPLETED ·Phase: PHASE2
-
Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma
NCT06550921 ·Status: RECRUITING ·Phase: NA
-
Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma
NCT01570166 ·Status: UNKNOWN ·Phase: NA
-
The Efficacy of Transarterial Chemoinfusion (TAI) Combine Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma (HCC)
NCT03851887 ·Status: UNKNOWN ·Phase: PHASE2
-
Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma
NCT05717738 ·Status: RECRUITING
-
Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT
NCT05225116 ·Status: RECRUITING ·Phase: PHASE1
-
Radiofrequency Ablation Combined With Recombinant Human Adenovirus Type 5 in the Treatment of Hepatocellular Carcinoma.
NCT03790059 ·Status: UNKNOWN ·Phase: NA
-
Stereotactic Body Radiotherapy Versus Radiofrequency Ablation for Unresectable, Small (≤ 3 cm) HCC
NCT05433701 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
The Synergistic Effect of Portal Venous Supply Control and Immunotherapy in Hepatocellular Carcinoma
NCT05760430 ·Status: UNKNOWN ·Phase: PHASE2
-
Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
NCT01850667 ·Status: COMPLETED ·Phase: PHASE2
-
Observational Study on Patients With Hepatobiliary Tumors
NCT04637048 ·Status: UNKNOWN
-
The Efficacy and Safety of EOB-MRI Guided Microwave Ablation for Early HCC: A Multicenter, Prospective, Observational Study
NCT06096896 ·Status: ACTIVE_NOT_RECRUITING
-
Adjuvant Radiotherapy for Resected Hepatocellular Carcinoma With MVI
NCT04891874 ·Status: COMPLETED ·Phase: NA
-
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
NCT05713994 ·Status: RECRUITING
-
Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma
NCT06530784 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma ≤ 5 cm
NCT01825824 ·Status: UNKNOWN ·Phase: PHASE2
-
The Efficacy of Sequential RT After Triple Therapy for uHCC
NCT07052448 ·Status: ENROLLING_BY_INVITATION